GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Gross Profit

TherapeuticsMD (TherapeuticsMD) Gross Profit : $1.30 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Gross Profit?

TherapeuticsMD's gross profit for the three months ended in Dec. 2023 was $0.50 Mil. TherapeuticsMD's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $1.30 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. TherapeuticsMD's gross profit for the three months ended in Dec. 2023 was $0.50 Mil. TherapeuticsMD's Revenue for the three months ended in Dec. 2023 was $0.50 Mil. Therefore, TherapeuticsMD's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

TherapeuticsMD had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of TherapeuticsMD was 98.00%. The lowest was 45.51%. And the median was 78.38%.


TherapeuticsMD Gross Profit Historical Data

The historical data trend for TherapeuticsMD's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Gross Profit Chart

TherapeuticsMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.31 48.90 1.17 68.57 1.30

TherapeuticsMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.57 0.42 0.44 -0.05 0.50

Competitive Comparison of TherapeuticsMD's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Gross Profit distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Gross Profit falls into.



TherapeuticsMD Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

TherapeuticsMD's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1.302 - 0
=1.30

TherapeuticsMD's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.502 - 0
=0.50

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.30 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

TherapeuticsMD's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.50 / 0.502
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


TherapeuticsMD  (NAS:TXMD) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

TherapeuticsMD had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


TherapeuticsMD Gross Profit Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD (TherapeuticsMD) Business Description

Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
Executives
Marlan D Walker officer: General Counsel 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler officer: Principal Financial Officer 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan officer: CAO and VP of Finance 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman officer: Chief Business Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts director C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro director
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jules A. Musing director 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Collins Cooper C. director 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354

TherapeuticsMD (TherapeuticsMD) Headlines

From GuruFocus

TherapeuticsMD Announces First Quarter 2023 Financial Results

By Business Wire Business Wire 05-15-2023

SHAREHOLDER ALERT: Weiss Law Investigates TherapeuticsMD, Inc.

By PRNewswire PRNewswire 07-10-2022

This Insider Just Sold Shares of TherapeuticsMD Inc

By GuruFocus Research GuruFocus Editor 12-10-2022